Epigral Limited (Epigral), India’s leading integrated chemical manufacturer, announced its financial results for the quarter ended June 30, 2025. The company posted a revenue of Rs. 615 crore for the quarter ended June 30, 2025 as against Rs. 654 crore recorded in Q1YF25. During the quarter under review, PAT stood at Rs. 160 crore (includes decrease in deferred tax liability of Rs. 81 crore) compared to Rs. 86 crore in Q1FY25.

Commenting on the results, Maulik Patel, Chairman and Managing Director, Epigral said: “Q1FY26 quarter ended with slightly lower volume and drop in realizations, however we maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2FY26 to be stronger compared to H1FY26.

Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase. Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget. We are still left with a land parcel in the current complex for which we will announce a capex to further strengthen our integrated complex.

We are working on the new chemistry at our new land parcel. This new chemistry project will be on similar lines of our earlier projects, i.e. import substitution products where demand is expected to grow in double digits and where we can generate good ROCE.

We continue our journey to move forward in our direction of scalability with profitability, trengthening our integration and creating value for our stakeholders,” Patel added.

Key performance highlights:

Q1FY26 Operational and Financial Highlights:

* Plant utilization stood at 73%

* ROCE grew to 24% as on 30th June 2025 vs 21% as on 30th June 2024 due to improved earnings

* Net Debt/EBITDA reduced to 0.6x as on 30th June 2025 vs 1.6x as on 30th June 2024 on account of improvement in EBITDA and reduction in Net Debt

* YoY Revenue dropped by 6% to Rs. 615 crore. Revenue contribution from Derivatives & Specialty business stood at 50%

*EBITDA dropped by 7% to Rs. 163 crore, however EBITDA margin remained unchanged at 27% on account of sustained focus on efficiency and product mix

* PAT stood at Rs.160 crore, however PAT excluding deferred tax liability benefit stood at Rs. 79 crore as against Rs. 86 crore in Q1FY25